Text Size

Investigation Into the Differentiation of Tumour and Healthy Brain Tissue Using Multi-exponential T2 Components

This study is currently recruiting participants.
Verified April 2012 by Alberta Health Services
Sponsor:
Information provided by (Responsible Party):
Alberta Health Services
ClinicalTrials.gov Identifier:
NCT00813787
First received: December 19, 2008
Last updated: April 4, 2012
Last verified: April 2012
History of Changes

December 19, 2008
April 4, 2012
February 2009
May 2012   (final data collection date for primary outcome measure)
T2 characteristics of glioma tissue versus normal [ Time Frame: Before radiotherapy treatment begins ] [ Designated as safety issue: No ]
T2 characteristics of glimoa tissue versus normal [ Time Frame: Before radiotherapy treatment begins ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00813787 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Investigation Into the Differentiation of Tumour and Healthy Brain Tissue Using Multi-exponential T2 Components
Investigation Into the Differentiation of Tumour and Healthy Brain Tissue Using a Specialized MRI Technique Called Multiexponential T2 Component Analysis

The purpose of this study is to see if a specialized imaging technique using MRI called multi-exponential T2 component analysis can reliably differentiate between normal brain and brain tumour.

Existing methods of contouring tumours for radiation therapy involve manual interpretations of qualitative diagnostic images. These methods, being qualitative, do not offer a consistent and reproducible platform for contouring, making it difficult to evaluate the effects of contouring choices on treatment outcome. T2 component analysis in MRI has the potential to offer a quantitive basis for identifying tumor tissue- this potential is investigated in this pilot study.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

A. Any glioma patient who recieves treatment at our clinic (Cross Cancer Institute) who agrees to take part in the study.

B. Any normal volunteer who agrees to take part in the study.
Glioma
Not Provided
  • A. glioma
    A. glioma population
  • B. Normal brain
    B. Normal brain
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
20
May 2012
May 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Eighteen years of age or older
  • Clinical subjects must have not yet begun radiation therapy
  • Must have signed our study-specific consent form

Exclusion Criteria:

-
Both
18 Years and older
Yes
Contact: Keith Wachowicz, PhD (780) 989-4334 keithwac@cancerboard.ab.ca
Canada
 
NCT00813787
CNS-24534
Yes
Alberta Health Services
Alberta Health Services
Not Provided
Study Chair: Keith Wachowicz, PhD Alberta Health Services
Alberta Health Services
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP